Novartis · 1 day ago
Sr. Project Engineer (Design & Const.)
Novartis is a leading pharmaceutical company, and they are seeking a Sr. Project Engineer to lead the development and execution of CAPEX projects. This role involves strategic planning, technical solution implementation, and ensuring compliance with internal standards and regulatory requirements while enhancing operational performance.
BiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Drive end-to-end planning, execution, and reporting of CAPEX projects
Develop and implement project execution strategies aligned with cost, schedule, and quality goals
Prepare and manage technical documentation including specifications, drawings, and risk assessments
Oversee vendor and contractor performance to ensure timely and compliant project delivery
Execute commissioning, qualification, and validation activities for new equipment and systems
Ensure compliance with internal standards, regulatory requirements, and safety protocols
Support audits and contribute to continuous improvement through technical troubleshooting and training
Qualification
Required
Bachelor's degree in engineering or relevant discipline
Minimum 5 years of engineering experience, including a minimum of 2+ years' experience with CAPEX investment projects within the pharmaceutical industry
Proven leadership in managing external engineering resources
Strong project management skills, including contract oversight and budget control
Experience collaborating across engineering functions to deliver integrated project outcomes
In-depth understanding of HSE standards and GxP/QA compliance
Preferred
Diverse pharmaceutical experience preferred; large molecule, small molecule, aseptic drug substance and aseptic drug product
Benefits
Health, life and disability benefits
401(k) with company contribution and match
Generous time off package including vacation, personal days, holidays and other leaves
Company
Novartis
Novartis is a pharmaceutical company that researches and develops medicines for serious diseases to improve and extend people's lives.
Funding
Current Stage
Public CompanyTotal Funding
$2.49BKey Investors
Bill & Melinda Gates Foundation
2024-06-19Post Ipo Debt· $2.49B
2018-02-14Grant· $6.5M
2000-05-19IPO
Leadership Team
Recent News
2026-02-06
2026-02-06
Longevity.Technology
2026-02-06
Company data provided by crunchbase